Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Spektron Systems

Spektron Systems
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$2.5M LATEST DEAL AMOUNT
Description

Provider of a drug discovery platform intended to design small molecule type drugs. The company's platform associates biological effect to chemical attributes through a 'Top Down' methodology that facilitates the assessment of systemic endpoints in addition to the specific biochemical pathway and receptor binding profiles within the pathway, enabling drug researchers to increase drug discovery speed while decreasing cost through a reduction in the number of compounds synthesized.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Social/Platform Software
Primary Office
  • 400 West Capitol Avenue
  • 17th Floor
  • Little Rock, AR 72201
  • United States

+1 (800) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Spektron Systems’s full profile, request a free trial.

Spektron Systems Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Angel (individual) 03-Jan-2018 $2.5M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Spektron Systems Executive Team (3)

Name Title Board
Seat
Contact
Info
Thaddeus Moskal Co-Founder & Chief Executive Officer
Cara Condray-Azhar Corporate Communications Specialist ll
David Wolf MD Co-Founder, President, Chief Medical Officer & Scientific Advisor